About

NeuraVia, Inc. is inviting angel investors, venture partners, and healthcare-aligned funds to apply to partner with us in transforming Alzheimer’s care through AI. We are a Delaware C-Corp pioneering the world’s first at-home Alzheimer’s progression AI model, integrating multimodal data (neuroimaging, clinical, and biomarkers) into a predictive deep learning framework. Our mission is to make progression monitoring accessible, accurate, and cost-effective. About Us: Originated from NeuraVia Research Inc., a 1,000+ member global nonprofit. Partnerships established in Canada, U.S., Nigeria, and India. U.S. for-profit arm launched to accelerate commercialization. Investment Details: Raising a $400k pre-seed round via SAFE (Delaware C-Corp, $5m cap). Early commitments already secured. Funding will support model training/deployment, global pilots (2026), and regulatory approvals in India, Nigeria, and North America. Why Join Us as an Investor: Addressing a $13B+ Alzheimer’s diagnostics and progression market. Global hospital partnerships across three continents. SaaS + hospital licensing model with strong early demand. Led by an international advisory team of neurologists, AI researchers, and clinical trial experts. We are actively looking for investors to join our journey. If you’re interested in early-stage healthcare AI ventures, apply to connect and receive more details about NeuraVia’s roadmap and growth strategy.